Clinical Trial Search

Phase 3 N=474 Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136

Measles · Varicella · Mumps

Primary: Number of Subjects Seroconverted for Measles, Mumps, Rubella and Varicella Zoster Virus (VZV) Antibodies Above the Cut-off Values — 294; 155; 262; 145 Participants…

GlaxoSmithKline Results Apr 2017 7.8% serious AE View details

Phase 3 N=281 Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis

Ulcerative Colitis

Primary: To Achieve Clinical Remission in Subjects With Active Ulcerative Colitis (UC). — 42; 29 participants — p=0.069

Tillotts Pharma AG Results Apr 2017 1.1% serious AE View details

Phase 3 N=68 Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD.

Pre-diabetes · Older Adults

Primary: Change in Weight Reported at 14 Weeks — -3.3; -6.8 kg — p=<0.05

Stanford University Results Apr 2017 11.8% serious AE View details

Phase 3 N=1,692 Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Primary: Percentage of Patients to Experience Any Treatment-emergent Adverse Event — 56.8; 65.9; 61.3; 67.5 Percentage of participants

AstraZeneca Results Apr 2017 7.3% serious AE View details

Phase 3 N=430 A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related Complications

Influenza

Primary: Number of Subjects Reporting Solicited Adverse Events (AEs) Following Vaccination With Either TIVc or TIV by Overall Age Group — 149; 41; 89; 18 Subjects

Novartis Vaccines Results Apr 2017 3.8% serious AE View details

Phase 3 N=72 Melatonin for Fatigue and Other Symptoms in Patients With Advanced Cancer

Cancer · Fatigue

Primary: Fatigue as Measured by the Physical Fatigue Scale in the The Multidimensional Fatigue Inventory (MFI) (Smets EM, Garssen B, Bonke B, et al., J Psychosom Res 39:315-325…

Bispebjerg Hospital Results Apr 2017 0.0% serious AE View details

Phase 3 N=89 Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study (PAINS)

Altitude Sickness

Primary: Acute Mountain Sickness — 19; 26 Participants

Stanford University Results Apr 2017 0.0% serious AE View details

Phase 3 N=103 Ultrasound Guided Supraclavicular Nerve Block

Local Anesthetic

Primary: Duration of Analgesia. — 7.5; 10 minute — p=0.14

The Cleveland Clinic Results Apr 2017 0.0% serious AE View details

Phase 3 N=79 Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD

COPD

Primary: Area Under the Curve for Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) From 0 to 12 Hours (AUC0-12) on Day 8 — 1.538; 1.516 Liter

Pearl Therapeutics, Inc. Results Apr 2017 2.0% serious AE View details

Phase 3 N=215 Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects With Acute Blunt Trauma Injuries

Acute Blunt Soft Tissue Injuries/Contusions

Primary: Sum of Pain Intensity Differences Over 24 Hours After Initiating Treatment (SPID 24) — 42.9; 45.5 units on a scale

Novartis Results Apr 2017 0.0% serious AE View details

Phase 3 N=10 Study of Icariin for Bipolar Disorder and Co-Occurring Substance Use Disorders

Bipolar Disorder · Substance Use Disorder

Primary: Change in Hamilton Rating Scale of Depression (HAMD) From Baseline to Week 8 (Exit) — 17.5; 9 HAMD scale units — p=.012

University of Texas Southwestern Medical Center Results Apr 2017 0.0% serious AE View details

Phase 3 N=25 Psychotherapy for Bipolar II Depression, Pilot Study, Phase II

Bipolar II Disorder

Primary: Number of Participants With Greater Than or Equal to 50% Reduction in Depression Scores, With a Mania Score Less Than or Equal to 10 — 4; 3; 10; 8 participants

University of Pittsburgh Results Apr 2017 0.0% serious AE View details

Phase 3 N=80 24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo

COPD

Primary: Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) 0-24 — 0.192; 0.112; -0.072 Liters

Pearl Therapeutics, Inc. Results Apr 2017 2.7% serious AE View details

Phase 3 N=64 Sleep and Tolerability Study: Comparing the Effects of Adderall XR and Focalin XR

Attention Deficit Hyperactivity Disorder

Primary: Sleep Start Time, and End Time as Determined by Actigraph and Sleep Diary Over 8 Weeks. — 2249; 2304; 2319; 2325 HHMM.SS

Seattle Children's Hospital Results Apr 2017 0.3% serious AE View details

Phase 3 N=43 24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI

COPD

Primary: FEV1 AUC0-24 on Day 29 — 0.166; -0.083 Liters

Pearl Therapeutics, Inc. Results Apr 2017 2.5% serious AE View details